The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Overview
Eli Lilly (NYSE: LLY) was second to market with a GLP-1 weight-loss drug, losing out to Novo Nordisk (NYSE: NVO). However, Eli Lilly's Mounjaro and Zepbound produce stronger weight-loss results than Novo Nordisk's Wegovy, and they quickly took the lead. Now, many on Wall Street see Eli Lilly as a GLP-1 stock, which it is. But that's not the full picture, as investors are overlooking a much broader business.
Eli Lilly has a GLP-1 weight-loss drug problem. The company's highly successful Mounjaro and Zepbound accounted for nearly two-thirds of its revenues in the first quarter of 2026. And with year-over-year revenue growth of 125% and 80%, respectively, these two drugs are clearly the driving force behind the company's earnings. It is understandable that Wall Street is highly focused on this segment of the business.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.